Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  protein tyrosine kinase >  PD04217903

PD04217903

Basic information Safety Supplier Related

PD04217903 Basic information

Product Name:
PD04217903
Synonyms:
  • PD04217903
  • 2-[4-[1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl]-1H-pyrazol-1-yl]ethanol
  • 2-(4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-1H-pyrazol-1-yl)ethanol
  • 2-[4-[1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl]-1H-pyrazol-1-yl]ethanol PF 04217903
  • PF 04217903 2-[4-[1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl]-1H-pyrazol-1-yl]ethanol
  • 2-{4-[1-(6-Quinolinylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-y l]-1H-pyrazol-1-yl}ethanol
  • PF-04217903;PF 04217903
  • 2-[4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyrazin-5-yl]pyrazol-1-yl]ethanol
CAS:
956905-27-4
MF:
C19H16N8O
MW:
372.38
Product Categories:
  • Inhibitors
Mol File:
956905-27-4.mol
More
Less

PD04217903 Chemical Properties

Boiling point:
718.1±60.0 °C(Predicted)
Density 
1.53
storage temp. 
Store at -20°C
solubility 
insoluble in EtOH; insoluble in H2O; ≥18.6 mg/mL in DMSO
form 
solid
pka
14.31±0.10(Predicted)
color 
White to off-white
More
Less

PD04217903 Usage And Synthesis

Uses

4-[1-(6-Quinolinylmethyl)-1H-1,2,3-triazolo[4,5-b]pyrazin-6-yl]-1H-pyrazole-1-ethanol is a potential targets for protein kinase inhibitors on the regulation of autophagy. A potent and selective c-MET receptor tyrosine kinase. Potent c-MET inhibitor.

Definition

ChEBI: 2-[4-[3-(6-quinolinylmethyl)-5-triazolo[4,5-b]pyrazinyl]-1-pyrazolyl]ethanol is a member of quinolines.

Biological Activity

pf-04217903 is an atp-competitive small-molecule inhibitor of c-met kinase with ki value of 4.8 nm [1].the c-met kinase is a kind of receptor tyrosine kinases (rtk) and plays critical roles in embryonic development and wound healing. activation of c-met by the exclusive ligand hepatocyte growth factor (hgf) triggers a serious of biological responses that collectively give rise to the invasive growth .in cancers, abnormal activation of c-mets correlates with tumor growth, formation of new blood vessels and subsequently poor prognosis. pf-04217903 is a highly selective inhibitor of c-met. it showed antitumor activity in tumor models where c-met is activated by mechanisms including c-met gene amplification, hgf/c-met autocrine loop formation or c-met overexpression [1].pf-04217903 showed more than 1000-fold greater selectivity against c-met kinase over 150 other kinases. when evaluated in a panel of human tumor and endothelial cell lines such as gtl-16, h1993 and ht29 cells, pf-04217903 showed inhibition of c-met with a mean ic50 value of 7.3 nm. pf-04217903 was also found to inhibit some mutant c-met including r988c (ic50 value of 6.4 nm), v1092i (ic50 value of 16 nm), h1094r (ic50 value of 3.1 nm), m1250t (ic50 value of 24 nm) and t11010i (ic50 value of 6.7 nm). besides that, pf-04217903 suppressed proliferation of c-met-amplified gtl-16 and h1993cells with ic50 values of 12 and 30 nm, respectively. it induced apoptosis in gtl-16 cells [1 and 2].in mice bearing injected gtl-16 tumors, administration of pf-04217903 showed dose-dependent c-met phosphorylation inhibition and antitumor efficacy. it inhibited the phosphorylation of c-met with ec50 value of 10 nm and suppressed tumor growth with ec50 value of 13 nm. moreover, pf-04217903 was found to affect the downstream signal transduction of c-met such as akt, stat5 and gab-1 [1].

References

[1] zou h y, li q, lee j h, et al. sensitivity of selected human tumor models to pf-04217903, a novel selective c-met kinase inhibitor. molecular cancer therapeutics, 2012, 11(4): 1036-1047.
[2] cui j j, mctigue m, nambu m, et al. discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-met) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1 h-[1, 2, 3] triazolo [4, 5-b] pyrazin-6-yl)-1 h-pyrazol-1-yl) ethanol (pf-04217903) for the treatment of cancer. journal of medicinal chemistry, 2012, 55(18): 8091-8109.

PD04217903Supplier

Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
Chembest Research Laboratories Limited
Tel
+86-21-20908456
Email
sales@BioChemBest.com
Nanjing Chemlin Chemical Co., Ltd
Tel
025-83697070
Email
info@chemlin.com.cn
Jinan Trio PharmaTech Co., Ltd.
Tel
+86 (531) 88811783
Email
sales@trio-pharmatech.com (International market)
ChemCell Biomedicine Co.,Ltd.
Tel
020-13556033878 2965585218 13556033878
Email
chemcell@hotmail.com
More
Less

PD04217903(956905-27-4)Related Product Information